INTRODUCTION
Although there are relatively few drugs which have been used extensively as effective antimalarial agents, there has been little agreement concerning which dosage or which combination of drugs gives the best clinical effect (1) . The literature has been full of conflict and confusion about even the relatively simple matter of how best to terminate a clinical attack of malaria. It has been still more confused over the difficult problem of how to cure a malarial infection, in the sense of preventing the relapses which are otherwise so likely to occur. Part of the confusion has arisen from the fact that in the past most extensive studies on malaria had of necessity to be carried out in malarious regions, where it would be impossible to distinguish with certainty relapses from reinfections.
A reconditioning camp, established by the United States Army in Australia for the purpose of reconditioning men who had been infected with malaria in New Guinea, provided an almost ideal place for a precise study of relapse rates in naturally acquired malarial infections. It was situated in a nonmalarious region, so that the risk of confusing relapses with new infections was eliminated. The men sent to it lived under uniform conditions and were subjected to a uniform training schedule. The administration of suppressive atabrine or quinine was closely supervised. Two army hospitals, receiving at the time of the study large numbers of patients with malaria, were situated nearby. It was thus possible to study selected patients at these hospitals and then to have them transferred to the reconditioning center, where they could be closely followed for a period of time with suppressive therapy and for a longer period without suppression.
The main purpose of the work was the comparison of relapse rates after 4 different types of treatment of a clinical attack of malaria. This was supplemented by observations on the incidence of parasites in the peripheral blood during the time between clinical relapses, including a period of atabrine or quinine suppression, and during the onset of a clinical relapse. METHODS a. General. The men studied were from the 41st Division and were hospitalized for malaria, most of them for the first or second time, during the period extending from the middle of September to the end of December, 1943. Many of those observed during the earlier part of this period had recently returned from New Guinea. The men were given one of 4 different types of therapy. During treatment, drug levels were determined on the second and fifth days, and again on the ninth day in the case of the longer regimes. Blood smears were made and examined on each of the first 6 days of treatment, and on the ninth day if the therapy extended beyond 6 days. A careful temperature chart was kept for each man.
After discharge from the hospital, the men were placed on suppressive atabrine or quinine and were transferred to the reconditioning center as rapidly as circumstances permitted. Upon arrival at the reconditioning center each man was interviewed, and blood was taken for a drug level determination and a thick smear. Each man's suppressive treatment was continued until he had been on suppression for a total time of at least 3 weeks.
Suppression was then stopped. The men remained under observation until they relapsed, or if they did not relapse, until their transfer out of the reconditioning center. In the latter case, the period of observation off suppression varied from 4 to 11 weeks, but was usually 7 weeks. In order to reduce the extent of self-treatment, the nature of the special observations was explained to the men. They were specifically urged not to treat themselves with atabrine or quinine if they felt a malarial attack coming on, but instead to report to sick call and receive treatment at the station hospital, where a diagnostic blood smear could be obtained. As a further check on self-treatment, a drug level determination and a thick blood film were made on each man 3 to 4 weeks after the discontinuation of suppressive treatment. This was frequently repeated 2 weeks later. Men who showed a suspiciously high level of atabrine in the plasma were closely questioned. By these means a very appreciable number of relapses was discovered. Some of these patients entered the hospital a few days later, but others would have remained unknown to us if these observations had not been made.
b. Types of therapy. 1. Atabrine. This was the standard intensive oral atabrine treatment adopted by the army for the Southwest Pacific Area in September, 1943 . It consisted of 1.2 grams of atabrine during the first 24 hours, 0.8 gram during the second 24 hours, and 0.4 gram daily for the next 4 days (total 3.2 grams in 6 days).
2. Therapy 1 for the" first 6 days, followed by 5 days of plasmoquine hydrochloride, 0.02 or 0.03 gram per day. Suppressive atabrine, 0.1 gram per day, was given during this period of plasmoquine treatment. The atabrine was given after one meal, the plasmoquine after each of the other two meals.
3. Therapy 1 for the first 6 days, followed by 5 days of sulfamerazine, 3 or 4 grams per day. Here also, suppressive atabrine, 0.1 gram per day, was given during the period of sulfamerazine treatment.
4. Quinine, 3.0 grams per day for the first 3 days, then 2.0 grams per day for the next 3 days.
c. Suppressive treatments. 1. Atabrine, 0.1 gram per day every day except Sunday. This type of suppression followed each of types 1 to 3 of therapy and was continued for at least 3 weeks (usually 4 to 6 weeks).
2. Quinine, 0.6 gram (10 grains) per day. This was used after type 4 of therapy, and, like the atabrine suppression, was continued for at least 3 weeks.
d. Drug level determinations. Atabrine in the plasma was determined by the method of Brodie and Udenfriend (2) .
Quinine in the plasma was determined after the manner of Brodie and Udenfriend (3).
Sulfamerazine in whole blood was determined by the usual colorimetric method (4) .
e. Clinical observations. The clinical response to treatment was observed at MALARIA THEEAPY AND RELAPSE 45 the hospital. Special attention was paid to any possible toxic effects of the combinations of .drugs used. Where appropriate, brief clinical notes were made during the man's stay at the reconditioning center.
/. Parasitological observations. Thick blood films stained with Giemsa stain were relied on mainly. The parasite density was estimated by determining the number of parasites to 500 white blood cells. No smear was considered negative unless at least 500 white blood cells had been counted without the finding of a parasite.
RESULTS
a. Relapse rates. In vivax malaria, a relapse rate has little meaning unless it is expressed in relation to the time of observation since the preceding attack of malaria, or since the end of suppression if effective suppressive treatment has been administered. It is convenient to determine the weekly relapse rates and to cumulate these in order to get the total incidence of relapses at the end of any desired period of weeks off suppression. Such a cumulation is easily made if all of the men in a group who are originally placed under observation and who do not relapse remain under observation for the same length of time. Under such conditions the size of the population under study is affected only by the property being studied, i.e., relapses. Actually, in the present work, most of the men who did not relapse re- 
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WILLIAM TRAGER, F. B. BANG AND N. G. HAIRSTON mained under observation for 6 to 7 weeks off suppression, and hence through the period of maximum incidence of relapses. Circumstances beyond our control made it imperative for some men to leave the reconditioning center after only 5 weeks without suppression, while others stayed long enough to permit 10 to 11 weeks of observation off suppression. In order to compensate for this unavoidable decrease in the population studied, which was not due to relapses but to the men being transferred away from the center, the following type of calculation was made. It was assumed that in any group of men transferred out of camp the same percentage of relapses would have occurred during the ensuing week as actually occurred among the corresponding men who remained in camp. For example, if at 4 weeks off suppression 6 of 73 nonrelapsers were transferred out of the camp, and if at 5 weeks 13 (19 per cent) of the remaining 67 had relapses, then the .total relapses at 5 weeks would be counted as 13 plus 19 per cent of 6, or 14. Since most of the men were under observation for a fairly uniform period of time, this correction raised the final relapse rate at the end of the period of study to only a small and not statistically significant extent. Figure 1 shows for therapies 1 to 3 the cumulative weekly relapse rates after the discontinuation of suppression. It is noteworthy that all 3 curves have the same somewhat S-shaped form. The shape of these curves shows that the period of observation was long enough to cover the entire first wave of relapses which occurs after men infected with Plasmodium vivax have been taken off suppressive atabrine treatment. With therapies 1 to 3 followed by atabrine suppression, no relapses occurred during suppressive treatment. The peak incidence of relapses was at 4 or 5 weeks after the discontinuation of suppression (figure 3a, b, c), regardless of the therapy used. The height of the maximum atabrine plasma level observed during hospital treatment had no effect on the time required for the development of a relapse after the stoppage of suppression (table 5) . Similarly, this time was not affected by varying the time of suppression from as little as 3 weeks to as long as 14 weeks (table 6) . Figure 2 shows the cumulative relapse rate following the quinine therapy. This figure consists of 2 separate curves set side by side. The left-hand curve shows relapses which occurred while the men were taking suppressive quinine, with time expressed as weeks after the end of the quinine therapy of the preceding attack. The right-hand curve shows relapses which occurred after the men were off suppression, with time expressed as weeks after the end of quinine suppression. Two distinct waves of relapses obviously occurred, the first among men whose malaria could not be suppressed by 10 grains of quinine per day, the second among men whose malaria was suppressed by this amount of quinine. In each group the maximum incidence of relapses occurred at about 3 weeks after the change in quinine dosage, i.e., from 2 grams down to 0.6 gram per day for the first group, and from 0.6 gram to 0 for the second.
The final relapse rates are shown in table 1, with their differences and the standard errors of the differences. To be statistically significant, a difference must be at least 3 times its standard error. None of the differences are significant except the difference between Weeks during" quinine suppression the lowest rate (61 per cent) for the atabrine-plasmoquine groups and the highest rate (82 per cent) for the quinine group. This difference can probably be accounted for by the fact that the quinine therapy was not followed by adequate suppression.
The average maximal atabrine levels observed during treatment of the acute attack, and the average duration of atabrine suppression after the acute attack were approximately the same for the men who relapsed as for those who failed to relapse (tables 2 and 3), indicating that neither of these two factors has any effect on relapse rate. In the atabrinesulfamerazine group, the average blood levels of sulfamerazine were 7.0 milligrams for men who relapsed and 7.4 milligrams for the men who did not relapse.
In table 4 is presented a comparison of the final relapse rates of 4 different therapy groups after one and after two previous attacks of malaria. For 3 of the 4 therapy groups, there was no signifi- cant difference between the relapse rate of men who had had one previous attack and the rate of men who had had two previous attacks. However, a significant difference did appear in the atabrine group. The atabrine group was the only therapy group which included also an appreciable number of men who had had more than two attacks, and it is noteworthy that of these 39" men, 82 per cent relapsed. This was the same relapse rate as for the men who had had two attacks, and was again significantly different from the rate of 55 per cent for the men who had had only one attack. This higher relapse rate among the men with two or more attacks, combined with the fact that a relatively large number of such men was included only in the atabrine therapy group, accounts for the slightly (but not significantly) higher total relapse rate obtained with the atabrine group as compared with the atabrine-sulfamerazine or atabrine-plasmoq uine groups. Because of the small numbers of men involved, the relapse rates for the different therapies in the twoattack group do not differ significantly from each other. It is worthy of note that only mild symptoms of toxicity appeared when atabrine and plasmoquine were given on the same days but with different meals. Such toxieity as did appear was no greater than when plasmoquine alone was used. It was noted that there was a definite increase in the number of patients with toxic symptoms when the dose was increased from 0.02 to 0.03 gram of plasmoquine daily.
b. Time of occurrence of the relapse.
With the quinine treatment (therapy 4) followed by quinine suppression, 25 per cent of the men relapsed within 3 weeks after completion of the therapy and while taking 10 grains of quinine daily (figure 3d). After the discontinuance of suppression, a second wave of relapses occurred, with its peak incidence again at 3 weeks from the time of completion of suppressive treatment.
It is interesting to note that in men who have. been taking atabrine, the plasma level at first drops sharply after the cessation of atabrine. It then drops more slowly, and reaches an average level well below 10 micrograms per dayafter about 3 weeks. This course of events is illustrated in figure 4 . Evidently, the majority of clinical relapses develop within only 1 or 2 weeks after a low atabrine level has been reached.
c. The occurrence of parasites of P. vivax in the peripheral blood during the time between clinical relapses, including a period of atabrine or quinine suppression.
For these observations 25 volunteers were used who had just arrived at the reconditioning center. They had been discharged from the hospital, after treatment for malaria, about 1 to 3 weeks previously. Five had been treated with atabrine alone, 5 with atabrine and plasmoquine, 9 with atabrine and sulfamerazine, and 6 with quinine. The last 6 were on quinine suppression while all the others were on atabrine suppression. Suppression was continued at the camp until each man had been on suppression for 1 month following his discharge from the hospital. Hence the period of observation at the camp while on suppression varied from 10 days to 3 weeks. A thick blood film was prepared from each man every Monday, Wednesday, and Friday throughout the entire period of observation, which extended from the time of arrival at the center to either the time of relapse or the time of transfer out of the camp if no relapse occurred. The blood films were stained and examined for parasites in the usual manner.
Days
The results are summarized in table 7. The following facts appear at once. (a) During quinine or atabrine suppression positive smears containing a few parasites may be obtained just as frequently as during the period off suppression but preceding a definite relapse. (b) Eight of the 19 men on atabrine suppression and 4 of the 6 men on quinine suppression showed at least one positive smear. It happened that the 5 men treated for their attack with atabrine and plasmoquine were in the camp only 10 days when it was time to discontinue their suppression. This short period of observation while on suppression probably accounts for the failure to find a .positive smear on any of the plasmoquine group during this time, (c) The frequency of occurrence of positive smears either during or after suppression bore no relation to the eventual onset of a relapse. Thus patient no. 11 showed 5 scattered positive smears during a 70-day observation period, but had not relapsed when he left camp. On the other hand, patients nos. 1, 10, and 18 showed no positive smears until the onset of a definite relapse, (d) The relapse rate within the observation period of 50 days was 84 per cent for the 25 men. One man in each of the 4 treatment groups failed to relapse during his stay in camp.
d. Parasite counts in untreated vivax malaria. A series of parasite counts was obtained on each of 12 men, from the group of 25 used for the observations in the preceding section, during the development of their relapse but prior to the onset of clinical symptoms. The parasites usually showed at first a very rapid rate of increase unaccompanied by any clinical effects. Frequently, by the time distinct symptoms had appeared, impelling the person to seek hospital attention, the rate of parasite increase had slowed down considerably. Spontaneous decreases in parasite count occurred in 6 of this series of 12 persons. It was ascertained both from questioning of the individual and from quinine and atabrine determinations on blood samples that these parasite decreases were definitely not a result of self-treatment with antimalarial drugs. One man was followed over a relapse period of 16 days, during most of which time he felt essentially well. The initial rapid increase in parasites which occurred in the first 2 days was soon checked. The parasite density remained the same for 2 days, and in the next 5 days the parasite count decreased from 95 to only 18 per 500 white blood cells. Atabrine and quinine blood levels taken at this time were 0. The parasite count then again increased and a week" later reached a density of over 500 per 500 white cells. At this time a frank attack of clinical malaria developed. Before the end of suppression: observation period of 10 to 20 days 10(1); 6(1); 1(2) KD 17(1); 6 (1) 2 (1) 4 (1) 3 (1) 6(1); 1(1) 11(1); 6 (1) 8 (1) 4 ( A small series of patients at the station hospital was held without antimalarial treatment for about 24 hours after admission for a malarial relapse. At intervals during this time, thick blood films were prepared in such a manner as to permit a direct determination of the number of parasites per cu. mm. of blood. The results are presented in table 8 . In 8 of the 12 men, a definite decrease in the density of parasites in the peripheral blood occurred during the growing stage of the parasite, i.e., when it is developing from a ring to a mature trophozoite. In only one case (patient no. 8) was the extent of the decrease at all comparable to that regularly obtained following antimalarial therapy. Nevertheless, it is remarkable that even one case of 12 should have shown such a great decrease in parasite number in the complete absence of antimalarial treatment.
The sudden increase in rings which occurred in patient no. 12 cannot be accounted for on the basis of the small number of old parasites present in the peripheral blood 4 hours earlier. The slides prepared at 9:00 A.M. and at 1:30 P.M. were carefully checked over, and the counts confirmed, so that the sharp difference in parasite number cannot be the result of any obvious error. This patient, who was experiencing his tenth relapse, did not feel appreciably ill until very shortly after the time this increase in parasites in the peripheral blood had occurred. He then became so sick that antimalarial therapy had to be very promptly instituted.
DISCUSSION
In two thirds of the individuals studied, all of whom were infected with vivax malaria in the Southwest Pacific, a clinical relapse occurred within 3 to 5 weeks' after a suppressive level of drug ceased to be maintained in the plasma. In the group taking suppressive quinine, almost one third relapsed 3 to 5 weeks after the termination of the previous attack, with a further third relapsing 3 to 5 weeks after the end of suppressive treatment. No relapses occurred in the groups taking suppressive atabrine during the period of suppressive therapy.
The therapeutic regimes which were tried apparently affected only those forms of P. vivax which occurred in the peripheral blood and which produced the clinical attack. They evidently had no effect on the intrinsic cycle of development of those stages of the parasite which survive during the inter-relapse period and which are perhaps analogous to the cryptozoites demonstrated in avian malaria (5). The presence of small numbers of parasites in the peripheral blood, unaccompanied by symptoms, during adequate atabrine suppression also indicates that some tissue stage may be more or less continuously producing parasites into the peripheral blood. It is noteworthy that the parasites seen are almost invariably young forms. Presumably, in the presence of an adequate plasma level of atabrine, these young forms are unable to develop further. But if the administration of suppressive atabrine is stopped, they develop and multiply, and ultimately give rise to a clinical relapse. The level of atabrine which is maintained in the plasma has no effect on the appearance of these young forms, or on the eventual relapse after the atabrine has been discontinued. These facts are in general agreement with those reported by Fair ley (6) .P lasmoquine is the only drug which appears to have had at times a favorable effect in reducing the incidence of relapses of malaria (7) . In the present study it did not have a significant effect. Differences in the effects of a drug may be the result of differences in the strain of parasite on which it is acting. Certainly there are indications that the strain of vivax malaria present in the Southwest Pacific differs from that found in the United States (8) . However, in the light of recent results obtained with quinine and plasmoquine in relatively high dosage (9) , it may be concluded that the dose of plasmoquine, rather than the strain of parasite, is the important factor conditioning the -therapeutic response. SUMMARY 1. Primary and recurrent attacks of malaria due to Plasmodium vivax were treated by one of the following 4 therapeutic regimes: (a) intensive oral atabrine, 3.2 grams in 6 days; (6) intensive oral atabrine, 3.2 grams in 6 days followed by plasmoquine, 0.10 to 0.15 gram in 5 days; (c) intensive oral atabrine, 3.2 grams in 6 days followed by sulfamerazine, 15 to 20 grams in 5 days; (d) quinine, 15 grams in 6 days. In therapies 2 and 3 the plasmoquine or sulfamerazine was accompanied by suppressive atabrine. Regimes 1 to 3 were followed by suppressive atabrine, 0.6 gram weekly for a period usually of 4 to 7 weeks. The quinine treatment was followed by quinine suppressive therapy 10 grains daily for usually about 5 weeks. After the discontinuation of suppressive treatment the men were continued under observation for periods of 4 to 7 weeks or longer. The overall relapse rates within this period of observation for the different types of therapy were: atabrine, 76 per cent; atabrine-plasmoquine, 61 per cent; atabrine-sulfamerazine, 69 per cent; quinine, 82 per cent. The differences in the relapse rates following the 3 atabrine treatments were not statistically significant; however, the rate for the quinine therapy was significantly higher than that for atabrineplasmoquine.
Neither the plasma atabrine levels observed during therapy, nor the period of administration of suppressive atabrine, had any apparent effect on either the relapse rate or the time from the end of suppression to the maximum incidence of relapses.
2. A detailed study of 25 of the P. vivax cases, distributed almost evenly with respect to the type of therapy, demonstrated that scattered positive smears showing a small number of parasites occurred in most individuals, unaccompanied by symptoms, throughout the inter-relapse period, both during and after suppression.
3. In the individuals referred to in (c) above, it was possible to observe the changes in parasite number during the period just preceding the onset of a clinical relapse. In some individuals the numbers of parasites decreased appreciably previous to treatment, thus presumably indicating an action by the defense mechanism of the host. Parasite counts over a 20-hour period in 12 cases be only half as many fully developed of hospitalized but untreated P. vivax schizonts as there had been young ones relapses showed that the number of para-20 hours previously. In one case a 90 sites usually decreased during the grow-per cent reduction in parasite number ing stage of the organisms. There might occurred within a single asexual cycle.
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